Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Fernando C FervenzaGerald B AppelSean J BarbourBrad H RovinRichard A LafayetteNabeel AslamJonathan A JeffersonPatrick E GipsonDana V RizkJohn R SedorJames F SimonEllen T McCarthyPaul BrenchleySanjeev SethiCarmen Avila-CasadoHeather BeanlandsJohn C LieskeDavid PhilibertTingting LiLesley F ThomasDolly F GreenLuis A JuncosLada Beara-LasicSamuel S BlumenthalAmy N SussmanStephen B EricksonMichelle HladunewichPietro A CanettaLee A HebertNelson R LeungJay RadhakrishnanHeather N ReichSamir V ParikhDebbie S GipsonDominic K LeeBruno R da CostaPeter JüniDaniel C Cattrannull nullPublished in: The New England journal of medicine (2019)
Rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. (Funded by Genentech and the Fulk Family Foundation; MENTOR ClinicalTrials.gov number, NCT01180036.).